查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017204

瘧疾疫苗市場：2026-2032年全球市場預測（依疫苗類型、年齡層、接種方案、最終用戶和接種途徑分類）

Malaria Vaccine Market by Vaccine Type, Age Group, Dosage Schedule, End User, Route Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，瘧疾疫苗市場價值將達到 3.4543 億美元，到 2026 年將成長至 3.7356 億美元，到 2032 年將達到 6.2332 億美元，複合年成長率為 8.79%。

主要市場統計數據
基準年 2025 3.4543億美元
預計年份：2026年 3.7356億美元
預測年份 2032 6.2332億美元
複合年成長率 (%) 8.79%

一個權威的瘧疾疫苗環境框架，將科學突破、政策路徑和實施現實聯繫起來，從而能夠做出切實可行的決策。

在免疫學進步、新型平台技術以及政策重點轉變的推動下，全球瘧疾疫苗研發的討論正從充滿希望的實驗階段轉向謹慎的部署規劃階段。近期臨床結果已證實多種疫苗方案的有效性，而實際免疫規劃也日益完善，準備評估其與現有公共衛生體系的整合。隨著研究機構、政府部門、非政府組織和私人醫療機構等各相關人員重新評估地方性疾病控制策略，對現狀進行簡明扼要、基於證據的分析對於做出明智的決策至關重要。

平台創新、加速監管和供應鏈現代化如何共同重新定義疫苗選擇、部署策略和專案可行性。

瘧疾疫苗領域正經歷變革時期，其特點是平台多樣化、監管法規不斷演變以及部署策略日趨完善。 mRNA和病毒載體平台已從實驗性候選疫苗發展成為具有臨床意義的領先候選疫苗。同時，蛋白質次單元和結合製劑繼續為免疫接種計畫提供具有吸引力且安全性良好的疫苗。此外，適應性試驗設計和加速監管正在縮短證據產生與政策制定之間的時間間隔，並加速從療效數據到流行地區試點實施的轉化。

了解關稅政策的變化如何重塑瘧疾疫苗供應鏈中的籌資策略、採購趨勢和區域製造重點。

主要經濟體貿易和關稅調整引發的政策轉變正對全球衛生供應鏈產生複雜的影響，尤其對疫苗採購和分發計畫造成衝擊。關稅結構的變化可能導致關鍵原料和單劑成品疫苗的到貨成本波動，影響製造地的選擇，並改變供應商和採購商之間的談判動態。對於瘧疾疫苗而言，由於其供應鏈可能包含多成分，例如用於mRNA的特殊脂質、病毒載體生產試劑以及填充和包裝服務，關稅差異會對籌資策略和交貨時間產生重大影響。

將疫苗平台、最終用戶角色、給藥途徑、年齡層和給藥時間表與專案適用性和策略重點聯繫起來的精細細分框架。

將瘧疾疫苗市場細分，可以發現不同的需求和決策標準，這些因素直接影響產品開發的優先事項和專案的實施。依疫苗類型分類，市場包括結合疫苗、減毒活病毒疫苗、mRNA疫苗、次單位疫苗和病毒載體疫苗。 mRNA疫苗又可細分為傳統mRNA疫苗及自擴增mRNA疫苗，病毒載體疫苗則進一步細分為腺病毒載體及MVA載體平台。每種疫苗在生產、穩定性和免疫抗原性方面都有其獨特的考量，這些考量會影響其在不同環境中的適應性。依最終用戶分類，市場生態系統涵蓋非政府組織、私人診所和公共免疫項目，其中公共免疫項目可進一步細分為區域性和國家性項目。每個最終用戶群體在採購計畫、資金籌措方式和低溫運輸要求方面都表現出不同的特徵。依給藥途徑分類，肌肉注射、口服和皮下注射等給藥方式在訓練、遵從性和廢棄物管理方面給第一線醫護人員帶來了不同的挑戰。根據年齡層別，青少年/成人、兒童和嬰兒需要進行相應的臨床評估和方案設計。兒童又可細分為學齡前兒童和學齡兒童，這反映了不同的疫苗接種平台和知情同意機制。根據接種方案，單劑、三劑和兩劑方案對後續系統、依從性策略和成本規劃提出了不同的要求。

區域在監管發展、生產能力和供應基礎設施方面的差異，決定了疫苗引進和推廣的個人化方法。

醫療基礎設施、監管管道和資金籌措模式的區域差異造成了不同的部署方案，這些都必須在策略規劃中加以考慮。在美洲，完善的監管機構和公私混合供應鏈支持在都市區早期部署，私人診所和慈善機構通常主導有針對性的試驗計畫。雖然該地區的供應鏈網路能夠處理複雜的配方，但在偏遠和農村地區，配送仍面臨挑戰，因此需要低溫運輸創新和社區合作策略。

開發商、製造商、物流供應商和專案合作夥伴之間的跨部門合作如何影響候選疫苗的實用性和部署途徑？

領先的生物製藥和生物技術公司、學術聯盟以及專業合約服務供應商都在共同塑造瘧疾疫苗的研發和部署過程。臨床開發人員正在推動各種平台技術的進步，而關於製劑穩定性、低溫運輸要求和給藥方案的策略性選擇正在影響專案合作夥伴試用和採用產品的意願。契約製造製造商和填充/包裝專家正在調整生產能力，以滿足對能夠同時支援小規模臨床用藥和大規模批量專案用藥的靈活生產需求，而物流供應商則在溫控運輸和最後一公里配送等領域不斷創新。

為平衡即時的實施需求、長期創新和具韌性的供應鏈策略，提出切實可行的方案和建議。

產業領導者應採取務實的、以投資組合為導向的方法，平衡短期可行性與長期技術投資。優先投資於與現有免疫基礎設施相契合的候選疫苗，特別是那些穩定性良好、給藥途徑更簡便的疫苗，同時繼續支持那些有望降低劑量、擴大免疫抗原性的創新平台。此外，還應加快與當地生產商和合約服務供應商的合作，以規避貿易和供應鏈風險，並縮短向流行地區的交付前置作業時間。

一種透明的、基於證據的調查方法，結合了同行評審的科學、監管趨勢和實施見解，使臨床特徵與專案實際情況相符。

本分析整合了一手和第二手資料，建構了瘧疾疫苗現況的多面圖。研究方法結合了對同行評審期刊、監管指導文件和臨床試驗註冊資料的文獻綜述，以及與疫苗學、供應鏈管理和公共衛生計畫實施領域的專家進行的結構化諮詢。此外，還查閱了現有免疫項目的實施後評估和營運報告（如有），以總結有關物流、合規性和社區接受度的經驗教訓。

將科學進展與操作需求聯繫起來的平衡和綜合分析，概述了實現瘧疾疫苗永續部署的現實路徑。

瘧疾疫苗研發的整體情況是謹慎樂觀，但受到操作複雜性的限制。科學進步拓寬了可用疫苗平台的選擇範圍，但其成功實施取決於產品特性與最終用戶、供應系統和當地供應鏈實際情況的契合度。監管方面的進展和新的資金籌措結構為加快疫苗分發創造了機會，但對低溫運輸物流、接種依從性和社區信任的認真考慮對於專案的成功至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：瘧疾疫苗市場：依疫苗類型分類

  • 結合疫苗
  • 減毒活病毒疫苗
  • 藥效疫苗
    • 常規mRNA
    • 自擴增mRNA
  • 次單位疫苗
  • 病毒載體疫苗
    • 腺病毒載體
    • MVA 向量

第9章：瘧疾疫苗市場：依年齡層別分類

  • 青少年和成年人
  • 兒童
    • 學前班
    • 學齡
  • 嬰兒

第10章：瘧疾疫苗市場劑量方案

  • 1. 接種疫苗
  • 接種疫苗 3 次
  • 兩劑疫苗

第11章：瘧疾疫苗市場：依最終用戶分類

  • NGO
  • 私人診所
  • 公共免疫計劃
    • 區域項目
    • 國家計劃

第12章：瘧疾疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 口服
  • 皮下

第13章：瘧疾疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 瘧疾疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 瘧疾疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國瘧疾疫苗市場

第17章：中國瘧疾疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bharat Biotech International Limited
  • BioNTech SE
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
Product Code: MRR-035DA3C63710

The Malaria Vaccine Market was valued at USD 345.43 million in 2025 and is projected to grow to USD 373.56 million in 2026, with a CAGR of 8.79%, reaching USD 623.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 345.43 million
Estimated Year [2026] USD 373.56 million
Forecast Year [2032] USD 623.32 million
CAGR (%) 8.79%

An authoritative framing of the malaria vaccine environment that connects scientific breakthroughs to policy pathways and implementation realities for practical decision-making

The global discourse around malaria vaccine development has shifted from hopeful experimentation to deliberate deployment planning, driven by advances in immunology, novel platform technologies, and shifting policy priorities. Recent clinical achievements have validated multiple vaccine approaches, while real-world immunization programs are increasingly prepared to evaluate integration into existing public health architectures. As stakeholders across research institutions, government agencies, non-governmental organizations, and private providers reassess endemic control strategies, a concise, evidence-based synthesis of the landscape becomes indispensable for informed decision-making.

This introduction frames the report's purpose: to present a clear, objective, and practice-oriented examination of scientific trajectories, delivery challenges, and stakeholder incentives shaping malaria vaccine adoption. By grounding the analysis in regulatory developments, route of administration considerations, end-user readiness, and age-specific vaccination strategies, the narrative connects laboratory breakthroughs with implementation realities. Ultimately, the intent is to provide leaders with the context they need to prioritize investments, design pilot programs, and align partners around durable, measurable public health outcomes.

How platform innovation, regulatory acceleration, and supply chain modernization are jointly redefining vaccine selection, deployment strategies, and programmatic feasibility

The malaria vaccine landscape has entered a transformative phase characterized by platform diversification, regulatory evolution, and more sophisticated deployment thinking. mRNA and viral vector platforms have migrated from experimental candidates to clinically relevant contenders, while protein subunit and conjugate formulations continue to offer established safety profiles that appeal to immunization programs. In parallel, adaptive trial designs and accelerated regulatory pathways have reduced latency between evidence generation and policy consideration, enabling faster transitions from efficacy data to pilot implementation in endemic regions.

Concurrently, supply chain and manufacturing innovations are reshaping potential scale-up scenarios. Advances in cold chain solutions, lyophilization approaches, and decentralized manufacturing models are mitigating historical constraints that limited vaccine reach. Financing mechanisms and public-private partnerships are also evolving to underwrite the early costs of introduction, while community engagement strategies have become more sophisticated, reflecting lessons learned from recent mass vaccination efforts. Taken together, these shifts herald a new era in which vaccine choices will be driven not only by efficacy but also by logistics, cost-efficiency, and programmatic fit across diverse health systems.

Understanding how evolving tariff policies reshape sourcing strategies, procurement dynamics, and regional manufacturing priorities for malaria vaccine supply chains

Policy shifts originating from trade and tariff adjustments in leading economies are affecting global health supply chains in complex ways, with tangible implications for vaccine procurement and distribution planning. Changes in tariff structures can alter the landed cost of critical inputs and finished vaccine doses, influence manufacturing site selection, and shift negotiation dynamics between suppliers and procurers. For malaria vaccines, which may rely on multi-component supply chains including specialty lipids for mRNA, viral vector production reagents, and fill-finish services, tariff differentials can meaningfully affect sourcing strategies and time-to-delivery considerations.

Moreover, tariff adjustments can prompt strategic supplier diversification as manufacturers and procurers seek to hedge policy risk. In some cases, incentives to localize certain production activities have been accelerated by tariff-related considerations, promoting regional manufacturing hubs that reduce exposure to cross-border trade frictions. These developments also influence procurement instruments used by international donors and national immunization programs, which may need to recalibrate tender specifications and contract terms to maintain affordability and predictability. In aggregate, tariff changes are a reminder that macroeconomic policy levers can cascade into operational decisions on vaccine availability and rollout timelines.

A nuanced segmentation framework linking vaccine platforms, end-user roles, administration routes, age cohorts, and dosing schedules to programmatic suitability and strategic priorities

Segmenting the malaria vaccine landscape reveals differentiated needs and decision criteria that directly influence product development priorities and programmatic adoption. Based on vaccine type, the market includes conjugate vaccines, live attenuated vaccines, mRNA vaccines, subunit vaccines, and viral vector vaccines, with mRNA further differentiated into conventional mRNA and self-amplifying mRNA, and viral vectors further partitioned into adenovirus vector and MVA vector platforms; each category carries unique manufacturing, stability, and immunogenicity considerations that affect suitability for various settings. Based on end user, the ecosystem spans non-governmental organizations, private clinics, and public immunization programs, with public immunization efforts further divided into local programs and national programs, and each end-user segment exhibits distinct procurement timelines, funding modalities, and cold chain expectations. Based on route of administration, intramuscular, oral, and subcutaneous options present different training, compliance, and waste-management implications for frontline health workers. Based on age group, adolescent and adult cohorts, children, and infants require tailored clinical evaluation and program design, with the child cohort further split into preschool and school-age populations to reflect divergent delivery platforms and consent mechanisms. Based on dosage schedule, single-dose, three-dose, and two-dose regimens impose varying logistical burdens on follow-up systems, adherence strategies, and cost planning.

Integrating these segmentation axes demonstrates that product selection cannot be siloed. For example, a self-amplifying mRNA candidate that promises dose-sparing properties may be attractive for national programs seeking to minimize cold chain strain, but its manufacturing footprint and regulatory maturity may present barriers for local pilot programs or private clinics. Similarly, an oral formulation that simplifies administration for infants could transform outreach campaigns, while a three-dose subunit schedule may align better with school-based delivery for preschool and school-age children if adherence supports are robust. Recognizing these cross-cutting dependencies allows stakeholders to prioritize portfolio investments, design appropriate delivery models, and align clinical development strategies with the operational realities of targeted end users.

Regional distinctions in regulatory readiness, manufacturing capacity, and delivery infrastructure that determine tailored approaches to vaccine introduction and scale-up

Regional variation in health infrastructure, regulatory pathways, and financing models creates divergent adoption scenarios that must be accounted for in strategic planning. In the Americas, established regulatory agencies and mixed public-private delivery landscapes favor early adoption in urban settings, with private clinics and philanthropic initiatives often leading targeted pilot programs. Supply chain networks in the region can support complex formulations, but remote and rural areas still present distribution challenges that require cold chain innovation and community engagement strategies.

Europe, Middle East & Africa encompasses a broad set of realities where robust regulatory harmonization in some European markets contrasts with infrastructure constraints in parts of the Middle East and Africa. National immunization programs in Africa are increasingly central to introduction planning, and regional collaboration on manufacturing and procurement is gaining traction as a means to reduce dependency on distant suppliers. Meanwhile, the Middle East offers opportunities for regional manufacturing and logistics hubs that can serve adjacent endemic markets, contingent on investment in local capacity and regulatory alignment.

Asia-Pacific presents a heterogeneous landscape as well, with several countries demonstrating strong manufacturing capabilities, sophisticated public immunization infrastructures, and capacity for large-scale vaccine diplomacy. In Southeast Asia and parts of South Asia, dense population centers provide implementation advantages, but varied regulatory timelines and financing mechanisms necessitate tailored entry strategies. Across all regions, localized community engagement, training for health workers, and integration with existing routine immunization schedules remain central to successful introduction.

How cross-sector collaboration among developers, manufacturers, logisticians, and program partners is shaping candidate viability and introduction pathways

Leading biopharmaceutical and biotechnology organizations, academic consortia, and specialized contract service providers are all shaping the trajectory of malaria vaccine development and deployment. Clinical developers are advancing diverse platform technologies, and their strategic choices around formulation stability, cold chain requirements, and dosing regimens influence the willingness of programmatic partners to pilot and adopt products. Contract manufacturers and fill-finish specialists are adapting to the demand for flexible capacity that can support both small-scale clinical lots and larger programmatic batches, while logistics providers are innovating around temperature-controlled transport and last-mile delivery.

Partnership models have become more transactional and more strategic at once, with licensing agreements, co-development partnerships, and technology-transfer arrangements accelerating local production capabilities. Nonprofit organizations and multilateral initiatives remain critical conveners, enabling data-sharing, financing for initial introductions, and operational support for demonstration projects. Collectively, these actors are creating an ecosystem in which alignment on regulatory requirements, quality assurance, and real-world evidence generation will determine which vaccine candidates transition from trial settings into routine use.

Practical, program-aligned recommendations for balancing immediate implementation needs with long-term innovation and resilient supply chain strategies

Industry leaders should adopt a pragmatic, portfolio-oriented approach that balances near-term implementability with longer-term technological bets. Prioritize investments in candidates that align with existing immunization infrastructures, particularly those with favorable stability profiles and simple administration routes, while maintaining parallel support for innovative platforms that promise dose-sparing or broader immunogenicity. Concurrently, accelerate partnerships with regional manufacturers and contract service providers to hedge against trade and supply chain risks and to reduce lead times for delivery to endemic settings.

Strengthen engagement with public immunization authorities, local program managers, and community stakeholders early in development to incorporate programmatic constraints into trial design and post-introduction evaluations. Invest in workforce training, cold chain optimization, and adherence-support mechanisms tailored to dosage schedules and age-specific delivery points. Finally, establish flexible procurement frameworks that can accommodate multiple product types and dosing regimens, enabling swift adaptation as new clinical evidence and regulatory guidance emerge. Implementing these recommendations will enhance both the speed and sustainability of malaria vaccine adoption across diverse contexts.

A transparent, evidence-driven methodology combining peer-reviewed science, regulatory signals, and implementation insights to align clinical attributes with programmatic realities

This analysis synthesizes primary and secondary evidence to build a multidimensional view of the malaria vaccine environment. The research approach combined targeted literature review of peer-reviewed journals, regulatory guidance documents, and clinical trial registries with structured expert consultations across vaccinology, supply chain management, and public health program implementation. Where available, post-introduction evaluations and operational reports from existing immunization programs were reviewed to extract lessons on logistics, adherence, and community acceptance.

Data triangulation was used to reconcile differences across sources, and emphasis was placed on verifiable policy statements, published clinical endpoints, and documented implementation experiences. The methodology prioritized transparency in source selection and documented assumptions, and the analytical framework explicitly connected product attributes to programmatic constraints to ensure actionable relevance. Ethical considerations included the careful interpretation of clinical data and the avoidance of premature policy recommendations where evidence remains emergent.

A balanced synthesis that links scientific progress to operational imperatives and outlines the pragmatic paths toward sustainable malaria vaccine implementation

The cumulative picture of malaria vaccine development is one of cautious optimism tempered by operational complexity. Scientific advances have broadened the menu of viable vaccine platforms, but successful introduction will hinge on aligning product characteristics with the realities of end users, delivery systems, and regional supply chains. Regulatory momentum and novel financing structures create opportunities for faster uptake, yet programmatic success will require meticulous attention to cold chain logistics, dosing adherence, and community trust.

Looking ahead, the most promising pathways blend pragmatic short-term choices-favoring products that fit existing immunization workflows-with strategic investments in platform technologies and regional manufacturing capacity. By doing so, decision-makers can mitigate risks associated with trade policy, supply disruptions, and variable health system readiness, while preserving the potential for transformative impact on malaria burden in endemic regions. The objective remains clear: translate scientific progress into durable reductions in morbidity and mortality through thoughtfully designed and sustainably implemented vaccination strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Malaria Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
  • 8.2. Live Attenuated Vaccine
  • 8.3. Mrna Vaccine
    • 8.3.1. Conventional Mrna
    • 8.3.2. Self Amplifying Mrna
  • 8.4. Subunit Vaccine
  • 8.5. Viral Vector Vaccine
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Mva Vector

9. Malaria Vaccine Market, by Age Group

  • 9.1. Adolescent & Adult
  • 9.2. Child
    • 9.2.1. Preschool
    • 9.2.2. School Age
  • 9.3. Infant

10. Malaria Vaccine Market, by Dosage Schedule

  • 10.1. Single Dose
  • 10.2. Three Dose
  • 10.3. Two Dose

11. Malaria Vaccine Market, by End User

  • 11.1. Ngos
  • 11.2. Private Clinics
  • 11.3. Public Immunization Programs
    • 11.3.1. Local Programs
    • 11.3.2. National Programs

12. Malaria Vaccine Market, by Route Of Administration

  • 12.1. Intramuscular
  • 12.2. Oral
  • 12.3. Subcutaneous

13. Malaria Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Malaria Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Malaria Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Malaria Vaccine Market

17. China Malaria Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bharat Biotech International Limited
  • 18.6. BioNTech SE
  • 18.7. GlaxoSmithKline plc
  • 18.8. Janssen Pharmaceuticals, Inc.
  • 18.9. Merck & Co., Inc.
  • 18.10. Moderna, Inc.
  • 18.11. Novavax, Inc.
  • 18.12. Panacea Biotec Limited
  • 18.13. Pfizer Inc.
  • 18.14. Sanofi S.A.
  • 18.15. Serum Institute of India Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GCC MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 184. GCC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. G7 MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 214. G7 MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. NATO MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 224. NATO MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)